| Primary |
| Hypertension |
56.2% |
| Diabetes Mellitus |
4.9% |
| Drug Use For Unknown Indication |
3.9% |
| Renal Impairment |
3.9% |
| Essential Hypertension |
3.4% |
| Myocardial Ischaemia |
3.0% |
| Renal Disorder |
3.0% |
| Depression |
2.5% |
| Product Used For Unknown Indication |
2.5% |
| Alcohol Problem |
2.0% |
| Atrial Fibrillation |
2.0% |
| Epilepsy |
2.0% |
| Prophylaxis |
2.0% |
| Anxiety |
1.5% |
| Dermatomyositis |
1.5% |
| Pain |
1.5% |
| Thrombosis Prophylaxis |
1.5% |
| Back Pain |
1.0% |
| Blood Pressure |
1.0% |
| Cerebrovascular Accident |
1.0% |
|
| Renal Failure Acute |
13.0% |
| Hyponatraemia |
11.1% |
| Pregnancy |
7.4% |
| Renal Cell Carcinoma Stage Unspecified |
7.4% |
| Visual Acuity Reduced |
5.6% |
| Anaphylactic Shock |
3.7% |
| Cardio-respiratory Arrest |
3.7% |
| Cataract |
3.7% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.7% |
| Fall |
3.7% |
| Hyperkalaemia |
3.7% |
| Hypertension |
3.7% |
| Malaise |
3.7% |
| Myalgia |
3.7% |
| Nightmare |
3.7% |
| Pancreatitis Acute |
3.7% |
| Psoriasis |
3.7% |
| Retinal Disorder |
3.7% |
| Rhabdomyolysis |
3.7% |
| Shock |
3.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
25.0% |
| Hypertension |
23.0% |
| Product Used For Unknown Indication |
22.3% |
| Depression |
3.5% |
| Type 2 Diabetes Mellitus |
3.5% |
| Diabetes Mellitus |
2.7% |
| Rheumatoid Arthritis |
2.6% |
| Pain |
2.0% |
| Tooth Disorder |
2.0% |
| Essential Hypertension |
1.9% |
| Prophylaxis |
1.6% |
| Atrial Fibrillation |
1.3% |
| Benign Prostatic Hyperplasia |
1.3% |
| Hypercholesterolaemia |
1.3% |
| Chest Pain |
1.2% |
| Renal Impairment |
1.2% |
| Osteoporosis |
1.0% |
| Thrombosis Prophylaxis |
1.0% |
| Cerebrovascular Accident |
0.9% |
| Constipation |
0.9% |
|
| Renal Failure Acute |
27.9% |
| Renal Failure |
9.0% |
| Rhabdomyolysis |
7.4% |
| Visual Impairment |
5.7% |
| Hepatitis |
4.9% |
| Memory Impairment |
4.9% |
| Leukocytosis |
4.1% |
| Cataract |
3.3% |
| Hyponatraemia |
3.3% |
| Presyncope |
3.3% |
| Urinary Retention |
3.3% |
| Weight Decreased |
3.3% |
| Coronary Artery Bypass |
2.5% |
| Cytolytic Hepatitis |
2.5% |
| Dermatitis Exfoliative |
2.5% |
| Diarrhoea |
2.5% |
| Nausea |
2.5% |
| Osteonecrosis |
2.5% |
| Ovarian Cancer |
2.5% |
| Prothrombin Time Ratio Decreased |
2.5% |
|
| Concomitant |
| Hypertension |
23.1% |
| Drug Use For Unknown Indication |
17.0% |
| Product Used For Unknown Indication |
16.2% |
| Diabetes Mellitus |
5.7% |
| Rheumatoid Arthritis |
5.6% |
| Pain |
3.7% |
| Type 2 Diabetes Mellitus |
3.5% |
| Atrial Fibrillation |
3.0% |
| Prophylaxis |
2.7% |
| Osteoporosis |
2.6% |
| Depression |
2.6% |
| Hypercholesterolaemia |
2.5% |
| Thrombosis Prophylaxis |
1.8% |
| Unevaluable Event |
1.7% |
| Essential Hypertension |
1.6% |
| Hepatitis C |
1.5% |
| Anaesthesia |
1.4% |
| Sepsis |
1.3% |
| Renal Cell Carcinoma |
1.3% |
| Nausea |
1.2% |
|
| Thrombocytopenia |
9.5% |
| Vomiting |
9.5% |
| Weight Decreased |
8.9% |
| Renal Failure |
8.3% |
| Renal Failure Acute |
8.0% |
| Pyrexia |
7.1% |
| Toxic Skin Eruption |
5.3% |
| Pulmonary Embolism |
5.0% |
| Myocardial Infarction |
4.7% |
| Urinary Tract Infection |
4.5% |
| Weight Increased |
3.6% |
| Pneumonia |
3.3% |
| Vertigo |
3.3% |
| Atrial Fibrillation |
3.0% |
| Hepatocellular Injury |
3.0% |
| Somnolence |
3.0% |
| International Normalised Ratio Increased |
2.7% |
| Systemic Lupus Erythematosus |
2.7% |
| Hypertensive Encephalopathy |
2.4% |
| Hypoglycaemia |
2.4% |
|
| Interacting |
| Hypertension |
24.0% |
| Drug Use For Unknown Indication |
22.0% |
| Product Used For Unknown Indication |
22.0% |
| Diabetes Mellitus |
10.0% |
| Bronchitis |
4.0% |
| Arrhythmia |
2.0% |
| Arthralgia |
2.0% |
| Computerised Tomogram |
2.0% |
| Diabetes Mellitus Non-insulin-dependent |
2.0% |
| Epilepsy |
2.0% |
| Fungal Infection |
2.0% |
| Insulin-requiring Type 2 Diabetes Mellitus |
2.0% |
| Osteoarthritis |
2.0% |
| Thrombosis Prophylaxis |
2.0% |
|
| Renal Failure Acute |
35.7% |
| Hyperkalaemia |
14.3% |
| Vomiting |
14.3% |
| International Normalised Ratio Increased |
7.1% |
| Overdose |
7.1% |
| Psoriasis |
7.1% |
| Renal Failure Chronic |
7.1% |
| Total Lung Capacity Decreased |
7.1% |
|
